Cambridge, UK, 23 June 2022: Kuano is delighted to announce Antonio Benedetti as its new Executive Chairman. He brings more than 25 years of executive experience in the pharmaceutical and automotive industries. Before joining Kuano as Chairman, Mr Benedetti was CEO of Cycle Pharmaceuticals for 6 years. Under his leadership, Cycle has developed and launched several orphan drugs in the US, where patients are supported by a newly created HUB, and has expanded its presence globally. Before Cycle, Mr Benedetti was CEO of Magirus GmbH, one of the largest firefighting equipment manufacturers in the world, part of CNH Industrial Group. Formerly, he was Group CFO at Archimica Group Holding BV, a global API contract manufacturer. Antonio holds a master’s degree in economics and started his career at Fiat Group Automobiles, where he held several executive positions, mostly on international assignments.
Vid Stojevic, CEO, said:
“Having Antonio’s commercial input is of real value. Kuano will benefit from his skills and executive experience in strategic business planning at a time of commercialisation for the company. It’s great to have him on board and I take great pleasure in welcoming him to the team.”
Antonio Benedetti said:
“Kuano’s technology is ground-breaking with their unique approach to quantum chemistry, and expertise in AI/ML placing them at the forefront of drug discovery. I join the team at an exciting juncture: their technology is validated and commercial strategy becoming realised. I look forward to contributing to their commercial growth, and helping them on their journey to create first-in-class drugs for intractable enzyme targets.”